Is Artelo Biosciences, Inc. (ARTLW) a Buy, Sell, or Hold?
NASDAQ : ARTLW
Artelo Biosciences, Inc.
$0.0056 USD
$0 (0.0%)
- Volume
- 29.4K
- Average Volume
- 6.48K
- Market Capitalization
- $13.07K
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.01
- Year Low
- $0.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.79
Company Overview
NASDAQ
Gregory D. Gorgas
Biotechnology
Healthcare
ARTLW
5
US
USD
Liquidity Metrics
0.11
1.79
1.79
1.76
0.00
Sales & Valuation
-$
0.00
0.00
0.00
-10.98
Profitability
-$5.47
-$12.88M
0.00%
0.00%
-1602.50%
-107.57%
P/E Metrics
0.00
0.00
0.00
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-8.86
4/9
$4.59M
$12.52M
$5.85M
-$7.3M
Key Metrics (TTM)
-$9.5M
0.00
1.34
1.79
-1602.50%
-157.72%
-325367.29%
-62085.85%
0 days
Company Executives
| Name | Title |
|---|---|
| Gregory D. Gorgas | President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary & Director |
| Andrew Yates | Senior Vice President & Chief Scientific Officer |
| Steven D. Reich | Chief Medical Officer |
| Jason H. Baybutt | Senior Vice President of Finance |
Poll Results
No votes yet today — be the first to share your view!
About Artelo Biosciences, Inc. (NASDAQ:ARTLW) Stock
Artelo Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing and commercializing therapeutic agents that interact with the endocannabinoid system. The company's portfolio of drug candidates features ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is currently undergoing Phase 1b/2a clinical trials for the management of anorexia linked to cancer. Another promising candidate is ART12.11, a synthetic cannabidiol cocrystal being explored for its potential in treating inflammatory bowel disease and post-traumatic stress disorder (PTSD). Additionally, ART26.12, a fatty acid binding protein 5 inhibitor, is in development to address breast and prostate cancer, neuropathic and nociceptive pain, and various anxiety disorders, inc ... luding PTSD. The company, initially incorporated in 2011 as Reactive Medical, Inc., was rebranded as Artelo Biosciences, Inc. in April 2017 and is headquartered in Solana Beach, California.
Frequently Asked Questions
-
What is the current Artelo Biosciences, Inc. (ARTLW) stock price?
-
Artelo Biosciences, Inc.(NASDAQ:ARTLW) stock price is $0.0056 in the last trading session. During the trading session, ARTLW stock reached the peak price of $0.0056 while $0.0056 was the lowest point it dropped to. The percentage change in ARTLW stock occurred in the recent session was 0.0% while the dollar amount for the price change in ARTLW stock was $0.
-
ARTLW's industry and sector of operation?
-
The NASDAQ listed ARTLW is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ARTLW?
-
Gregory D. Gorgas | President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary & Director
Andrew Yates | Senior Vice President & Chief Scientific Officer
Steven D. Reich | Chief Medical Officer
Jason H. Baybutt | Senior Vice President of Finance
| -
How many employees does ARTLW have?
-
Number of ARTLW employees currently stands at 5. ARTLW operates from 505 Lomas Santa Fe, Solana Beach, CA 92075, US.
-
Link for ARTLW official website?
-
Official Website of ARTLW is: https://www.artelobio.com
-
How do I contact ARTLW?
-
ARTLW could be contacted at phone #858 925 7049 and can also be accessed through its website. ARTLW operates from 505 Lomas Santa Fe, Solana Beach, CA 92075, US.
-
How many shares of ARTLW are traded daily?
-
The average number of ARTLW shares traded daily for last 3 months was 6.48K.
-
What is the market cap of ARTLW currently?
-
The market value of ARTLW currently stands at $13.07K with its latest stock price at $0.0056